- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Neal Dave Explains Why Biosimilars Should Be Favored Over Reference Products
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses the potential for biosimilar utilization to grow and the reasons why his practice favors them over reference products.
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses the potential for biosimilar utilization to grow and the reasons why his practice favors them over reference products.
Transcript:
Would you say that there’s still plenty of room for growth of biosimilars in oncology, given current regimens and actual use relative to the need?
There's room. So, I can speak for where I work and I know we've gone all in on the biosimilars as they came out, specifically last year, and we're using close to 90%, and over 90% in some of the biosimilars that are out there. So, there's still a little bit of room even for us to grow. A lot of times what happens is a research protocol, like in our case, where it's mandated to use the brand [reference product], or it's maybe a payer that's doing that. But if we have the choice, in our case, we're using biosimilar because it does decrease the cost of care and it's essentially the same product. It's not entirely a generic, but you have the same effectiveness. And so, the FDA has approved it that way and so we've used them that way. Now, I don't know if that's the case across the whole health care spectrum, in every clinic and every hospital system. So, there is room, I think, still for growth for sure to decrease the overall cost of care.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
